Uh, MMF, azathioprine dosages for myasthenia gravis diagnosed patients.
Reading File
Finding Sources
Finding Sources
Searching PubMed
"myasthenia gravis"[MeSH Terms] AND ("azathioprine"[MeSH Terms] OR "mycophenolate mofetil"[MeSH Terms])
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have enough information to give a thorough, well-cited answer. Here's the complete summary:
MMF and Azathioprine Dosages in Myasthenia Gravis
Both drugs are steroid-sparing immunosuppressants used as chronic adjunct therapy in MG. They are slow-acting - neither provides rapid benefit and both may take months to show clinical effect.
Azathioprine (AZA)
| Parameter | Details |
|---|---|
| Starting dose | 50 mg/day (low, to check tolerance) |
| Target/maintenance dose | 2 to 3 mg/kg/day (typically 150-250 mg/day) |
| Titration | Start low for a few days; if tolerated, increase to target range |
| Onset of benefit | Slow - a significant response may not be evident for many months to a year |
| Role | Used alone in patients who cannot tolerate/fail prednisone, OR combined with corticosteroids in severe/refractory disease |
Key safety notes:
-
Monitor LFTs and CBC regularly
-
Check thiopurine methyltransferase (TPMT) activity before starting - approximately 3/100,000 persons are enzyme-deficient, putting them at risk for bone marrow toxicity. Many clinicians test this pre-treatment
-
Significant drug interactions: allopurinol (increases mercaptopurine toxicity markedly - reduce AZA dose by 75% if co-prescribed) and warfarin
-
Azathioprine is a prodrug converted to mercaptopurine, metabolized by TPMT
-
Avoid in pregnancy (teratogenic in animals; generally discontinued before conception)
-
Adams and Victor's Principles of Neurology, 12th Ed., p. 1451-1452
-
Goldman-Cecil Medicine, p. 4209
Mycophenolate Mofetil (MMF)
| Parameter | Details |
|---|---|
| Dose | 2000 mg/day (2 g/day), typically divided as 1 g twice daily |
| Pediatric dose | 30-50 mg/kg/day |
| Role | Steroid-sparing adjunct; often used when AZA is not tolerated |
| Onset of benefit | Slow (similar to AZA - months) |
Key safety notes:
-
Large controlled trials in MG showed disappointing results vs. smaller trials that suggested benefit - clinical improvement, when it occurs, tends to be modest
-
Contraindicated in pregnancy (teratogenic; stricter than AZA in this respect)
-
Risk of opportunistic infections and rare lymphoproliferative disorders with long-term use (case reports of CNS lymphoma)
-
Monitor CBC and renal function
-
Goldman-Cecil Medicine, p. 4209
-
Adams and Victor's Principles of Neurology, 12th Ed., p. 1452
Comparative Placement in MG Management
First-line: Pyridostigmine (symptomatic)
+
Immunosuppression: Prednisone (most consistently effective)
+
Steroid-sparing: Azathioprine 2-3 mg/kg/day OR MMF 2 g/day
|
Refractory: Rituximab, cyclosporine, tacrolimus, efgartigimod, eculizumab
Both AZA and MMF are listed alongside thymectomy, IVIG, and plasmapheresis as part of the 2016 consensus guidelines on MG management (Sanders et al., Neurology 2016). A recent systematic review (Prado et al., 2023, PMID 36967437) also examined methotrexate as an alternative steroid-sparer for cases resistant to AZA/MMF.
Bottom line: AZA is slightly better-evidenced for long-term steroid-sparing in MG and is preferred in many guidelines. MMF is a reasonable alternative, especially when AZA is not tolerated, but its large RCT evidence is weaker. Both require months before clinical benefit becomes apparent.
This is a shared conversation. Sign in to Orris to start your own chat.